Q1. Could you start by giving us a brief overview of your professional background, particularly focusing on your expertise in the industry?

I bring over two decades of leadership experience in clinical diagnostics and life sciences, with a strong focus on market development, commercial transformation, and strategic partnerships across India and South Asia.

My expertise spans Clinical Dx , Molecular diagnostics, genomics, and clinical workflows – Allergy , Autoimmunity, TDM ,Transplant Dx , where I have led high-growth portfolios, built large cross-functional teams, and driven double-digit growth while improving EBITDA.

I’ve worked extensively on scaling advanced technologies (NGS, PCR, clinical automation) in emerging markets—balancing innovation adoption with affordability and access, which is critical in this region.

 

Q2. How are evolving healthcare priorities across South Asia shaping demand for advanced diagnostics and genetic testing?

Healthcare priorities in South Asia are shifting from acute care to continuum-based care, driven by:

• Rising non-communicable diseases (NCDs)
• Increased health awareness and screening programs
• Government push for universal healthcare access
• Sample to report – POCT devices 

This is accelerating demand for:

• Early diagnostics and screening (oncology, Reproductive health , infectious diseases)
• Genetic testing and precision medicine, especially in oncology and rare diseases
• Decentralized testing models (tier 2/3 expansion)
• Make in India products to address Cost and Qulaity 
• CDSO – approval authority help to ease bottlenecks on prompt approvals 

Importantly, the region demands cost-optimized innovation, not just high-end technology.

 

Q3. How do you see the transition from reactive to preventive and personalized healthcare influencing long-term market dynamics?

The transition from reactive to preventive care is fundamentally reshaping the diagnostics value chain:

• Diagnostics is moving from confirmation tool → decision driver
• Growth in predictive testing, companion diagnostics, and cost controlled diagnosis 
• Increasing integration of genomics into routine clinical pathways

Long-term impact:

• Higher testing volumes per patient lifecycle
• Stronger clinical-lab integration
• Shift from product sales to solution ecosystems (data + diagnostics + services)

This creates a structural growth tailwind for diagnostics companies.

 

Q4. In what ways are partnerships with governments and public health bodies shaping access, affordability, and scale in diagnostics?

Partnerships with governments are critical for scale in India.

Key contributions:

• National screening programs (TB, Cancer, Mother and child health) drive volume scale
• PPP models enable access to advanced technologies in public systems
• Price regulation frameworks push companies to innovate on cost
• Govt subsidies to help innovation and reach 

Successful companies align with:

• Public health priorities
• Local manufacturing / “Make in India” initiatives
• Training and capacity-building programs

This is where execution capability matters more than just technology.

 

Q5. In what ways are customers prioritizing factors such as accuracy, turnaround time, scalability, and integration into existing workflows?

Customers today are far more outcome-driven and operationally focused.

Top priorities:

1. Accuracy & reliability 
2. Turnaround Time 
3. Scalability 
4. Workflow integration

Increasingly, customers are evaluating:

• Total cost of ownership (not just instrument price)
• Service uptime and digital connectivity

The shift is from product purchase to performance partnership.

 

Q6. How is the competitive landscape evolving between global life sciences companies and regional players in the diagnostics and genomics space?

The landscape is becoming more dynamic and fragmented:

Global Players - Strengths: Advanced technology / Strong R&D pipelines/ Global quality standards

Regional / Local Players – Strengths: Cost competitiveness / Faster localization / Strong distribution reach

Emerging Trend: Shift toward hybrid competition:

Global companies localizing manufacturing
Regional players upgrading technology

Winning factors going forward:

• Speed of innovation localization
• Service network strength
• Ability to offer integrated solutions (not just instruments)

 

Q7. If you were an investor looking at companies within the space, what critical question would you pose to their senior management?

If I were an investor, my key question to management would be:

How are you building a sustainable moat beyond products—particularly in terms of ecosystem integration, customer stickiness, and data-driven value creation?

Followed by:

• What % of revenue is recurring vs transactional?
• How scalable is your model across tier 2/3 markets?
• What is your strategy for localization vs import dependency?
• How resilient is your business to pricing pressure and regulation?
• How will you mature talent to next level to handle high end platforms and technology?
• What are investments on Innovation and R&D?